DOCSLIB.ORG

Pharmacogenomics of Ventricular Conduction in Multi-Ethnic Populations Amanda Seyerle Dissertation Committee

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacogenomics of Ventricular Conduction in Multi-Ethnic Populations Amanda Seyerle Dissertation Committee Pharmacogenomics of Ventricular Conduction in Multi-Ethnic Populations Amanda Seyerle Dissertation Committee: Christy Avery (chair) Kari North Eric Whitsel Til Stürmer Craig Lee 1 TABLE OF CONTENTS Page LIST OF TABLES ...................................................................................................................................... v LIST OF FIGURES ..................................................................................................................................... vi LIST OF ABBREVIATIONS ..................................................................................................................... vii LIST OF GENE NAMES ............................................................................................................................ ix 1. Overview .............................................................................................................................................. 1 2. Specific Aims ....................................................................................................................................... 3 3. Background and Significance ............................................................................................................ 4 A. Ventricular Conduction ......................................................................................................................... 4 A.1. Electrical Conduction of the Heart ................................................................................................ 4 A.1.1. Sodium Channels................................................................................................................... 6 A.1.2. Calcium Channels ................................................................................................................. 7 A.1.3. Potassium Channels .............................................................................................................. 8 A.2. Ventricular Conduction on the Electrocardiogram ....................................................................... 9 A.2.1. QT Interval ............................................................................................................................ 9 A.2.1.1. Heart Rate Correction Formulas for QT Interval ........................................................ 10 A.2.2. QRS Complex ...................................................................................................................... 12 A.2.3. JT Interval ........................................................................................................................... 12 B. QT Interval Prolongation .................................................................................................................... 13 B.1. Risk Factors ................................................................................................................................ 14 B.1.1. Acquired Clinical Conditions .............................................................................................. 14 B.1.2. Congenital Conditions ........................................................................................................ 14 B.1.3. Electrolyte Imbalances ........................................................................................................ 15 B.2. Drug-Induced QT Prolongation .................................................................................................. 16 B.2.1. QT-Prolonging Medications ............................................................................................... 16 B.2.1.1 Cardiac Medications ................................................................................................... 16 B.2.1.2 Non-Cardiac Medications ........................................................................................... 17 B.2.2. Prevalence of QT-Prolonging Medication Use ................................................................... 18 B.2.3. Clinical Considerations ...................................................................................................... 19 B.2.4. Mechanisms ......................................................................................................................... 19 B.3. Categorical Versus Continuous Measures of QT Prolongation .................................................. 20 B.4. Potential Clinical Outcomes of Prolonged QT............................................................................ 21 B.4.1. Arrhythmias ......................................................................................................................... 21 B.4.2. Coronary Heart Disease ..................................................................................................... 22 B.4.3. Chronic Heart Failure ........................................................................................................ 24 B.4.4. Stroke .................................................................................................................................. 24 B.4.5. Mortality ............................................................................................................................. 25 ii C. QT Interval Genetics ........................................................................................................................... 27 C.1. Heritability .................................................................................................................................. 27 C.2. Early Studies ............................................................................................................................... 28 C.2.1. Congenital Long and Short QT Syndrome .......................................................................... 28 C.2.2. Family/Twin Studies ............................................................................................................ 30 C.2.3. Candidate Gene Studies ...................................................................................................... 30 C.3. Genome-Wide Association Studies ............................................................................................ 31 C.3.1. Ion Channel Genes .............................................................................................................. 33 C.3.2. Novel Associations .............................................................................................................. 33 C.3.3. Replication in Multi-Ethnic Populations ............................................................................ 34 C.4. Gene-Environment Studies ......................................................................................................... 35 D. Thiazide Diuretics ............................................................................................................................... 35 D.1. Pharmacologic Characteristics .................................................................................................... 36 D.2. Indications of Use ....................................................................................................................... 37 D.2.1. Contraindications................................................................................................................ 38 D.3. Prevalence ................................................................................................................................... 38 D.4. Thiazide-Induced QT Prolongation ............................................................................................ 39 D.4.1. Pharmacoepidemiology ...................................................................................................... 39 D.4.2. Proposed Mechanisms ........................................................................................................ 41 E. Pharmacogenomics ............................................................................................................................. 42 E.1. Pharmacogenomics of QT-Prolonging Drugs ............................................................................. 42 E.2. Pharmacogenomics of Thiazide Diuretics .................................................................................. 44 E.2.1. Thiazide Diuretics and QT Prolongation ............................................................................ 45 F. Bias in Pharmacoepidemiologic and Pharmacogenomic Studies ....................................................... 45 G. Multi-Ethnic Populations .................................................................................................................... 47 H. Public Health Significance .................................................................................................................. 48 4. Research Plan .................................................................................................................................... 50 A. Overview ............................................................................................................................................. 50 B. Specific Aim 1 .................................................................................................................................... 50 B.1. Simulation Overview .................................................................................................................. 50 B.2. Simulation Parameters and Values ............................................................................................. 51 B.2.1. Covariates ..........................................................................................................................
Load more

Recommended publications
  • A Disease Spectrum for ITPA Variation: Advances in Biochemical and Clinical Research Nicholas E
    Burgis Journal of Biomedical Science (2016) 23:73 DOI 10.1186/s12929-016-0291-y REVIEW Open Access A disease spectrum for ITPA variation: advances in biochemical and clinical research Nicholas E. Burgis Abstract Human ITPase (encoded by the ITPA gene) is a protective enzyme which acts to exclude noncanonical (deoxy) nucleoside triphosphates ((d)NTPs) such as (deoxy)inosine 5′-triphosphate ((d)ITP), from (d)NTP pools. Until the last few years, the importance of ITPase in human health and disease has been enigmatic. In 2009, an article was published demonstrating that ITPase deficiency in mice is lethal. All homozygous null offspring died before weaning as a result of cardiomyopathy due to a defect in the maintenance of quality ATP pools. More recently, a whole exome sequencing project revealed that very rare, severe human ITPA mutation results in early infantile encephalopathy and death. It has been estimated that nearly one third of the human population has an ITPA status which is associated with decreased ITPase activity. ITPA status has been linked to altered outcomes for patients undergoing thiopurine or ribavirin therapy. Thiopurine therapy can be toxic for patients with ITPA polymorphism, however, ITPA polymorphism is associated with improved outcomes for patients undergoing ribavirin treatment. ITPA polymorphism has also been linked to early-onset tuberculosis susceptibility. These data suggest a spectrum of ITPA-related disease exists in human populations. Potentially, ITPA status may affect a large number of patient outcomes, suggesting that modulation of ITPase activity is an important emerging avenue for reducing the number of negative outcomes for ITPA-related disease.
    [Show full text]
  • Estimation of DNA Contamination and Its Sources in Genotyped Samples
    Gregory Zajac ORCID iD: 0000-0001-6411-9666 Estimation of DNA contamination and its sources in genotyped samples Gregory J. M. Zajac1; Lars G. Fritsche1; Joshua S. Weinstock1; Susan L. Dagenais2; Robert H. Lyons2; Chad M. Brummett3; Gonçalo. R. Abecasis1 1) Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI; MI; 2) Department of Biological Chemistry and DNA Sequencing Core, University of Michigan, Ann Arbor, MI; 3) Department of Anesthesiology, Division of Pain Medicine, University of Michigan Medical School, Ann Arbor, MI. Corresponding author: Gregory JM Zajac 734-763-5315 [email protected] University of Michigan School of Public Health - Department of Biostatistics 1415 Washington Heights Ann Arbor, MI 48109-2029 Grant Numbers: HG007022 Author Manuscript This is the author manuscript accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/gepi.22257. This article is protected by copyright. All rights reserved. Abstract Array genotyping is a cost-effective and widely used tool that enables assessment of up to millions of genetic markers in hundreds of thousands of individuals. Genotyping array data are typically highly accurate but sensitive to mixing of DNA samples from multiple individuals prior to or during genotyping. Contaminated samples can lead to genotyping errors and consequently cause false positive signals or reduce power of association analyses. Here, we propose a new method to identify contaminated samples and the sources of contamination within a genotyping batch.
    [Show full text]
  • The Sensors of the Pain Pathway
    Nociceptors: the sensors of the pain pathway Adrienne E. Dubin, Ardem Patapoutian J Clin Invest. 2010;120(11):3760-3772. https://doi.org/10.1172/JCI42843. Review Series Specialized peripheral sensory neurons known as nociceptors alert us to potentially damaging stimuli at the skin by detecting extremes in temperature and pressure and injury-related chemicals, and transducing these stimuli into long- ranging electrical signals that are relayed to higher brain centers. The activation of functionally distinct cutaneous nociceptor populations and the processing of information they convey provide a rich diversity of pain qualities. Current work in this field is providing researchers with a more thorough understanding of nociceptor cell biology at molecular and systems levels and insight that will allow the targeted design of novel pain therapeutics. Find the latest version: https://jci.me/42843/pdf Review series Nociceptors: the sensors of the pain pathway Adrienne E. Dubin1 and Ardem Patapoutian1,2 1Department of Cell Biology, The Scripps Research Institute, La Jolla, California, USA. 2Genomics Institute of the Novartis Research Foundation, San Diego, California, USA. Specialized peripheral sensory neurons known as nociceptors alert us to potentially damaging stimuli at the skin by detecting extremes in temperature and pressure and injury-related chemicals, and transducing these stimuli into long-ranging electrical signals that are relayed to higher brain centers. The activation of functionally distinct cutaneous nociceptor populations and the processing of information they convey provide a rich diversity of pain qualities. Current work in this field is providing researchers with a more thorough understanding of nociceptor cell biology at molecular and systems levels and insight that will allow the targeted design of novel pain therapeutics.
    [Show full text]
  • The Mineralocorticoid Receptor Leads to Increased Expression of EGFR
    www.nature.com/scientificreports OPEN The mineralocorticoid receptor leads to increased expression of EGFR and T‑type calcium channels that support HL‑1 cell hypertrophy Katharina Stroedecke1,2, Sandra Meinel1,2, Fritz Markwardt1, Udo Kloeckner1, Nicole Straetz1, Katja Quarch1, Barbara Schreier1, Michael Kopf1, Michael Gekle1 & Claudia Grossmann1* The EGF receptor (EGFR) has been extensively studied in tumor biology and recently a role in cardiovascular pathophysiology was suggested. The mineralocorticoid receptor (MR) is an important efector of the renin–angiotensin–aldosterone‑system and elicits pathophysiological efects in the cardiovascular system; however, the underlying molecular mechanisms are unclear. Our aim was to investigate the importance of EGFR for MR‑mediated cardiovascular pathophysiology because MR is known to induce EGFR expression. We identifed a SNP within the EGFR promoter that modulates MR‑induced EGFR expression. In RNA‑sequencing and qPCR experiments in heart tissue of EGFR KO and WT mice, changes in EGFR abundance led to diferential expression of cardiac ion channels, especially of the T‑type calcium channel CACNA1H. Accordingly, CACNA1H expression was increased in WT mice after in vivo MR activation by aldosterone but not in respective EGFR KO mice. Aldosterone‑ and EGF‑responsiveness of CACNA1H expression was confrmed in HL‑1 cells by Western blot and by measuring peak current density of T‑type calcium channels. Aldosterone‑induced CACNA1H protein expression could be abrogated by the EGFR inhibitor AG1478. Furthermore, inhibition of T‑type calcium channels with mibefradil or ML218 reduced diameter, volume and BNP levels in HL‑1 cells. In conclusion the MR regulates EGFR and CACNA1H expression, which has an efect on HL‑1 cell diameter, and the extent of this regulation seems to depend on the SNP‑216 (G/T) genotype.
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • Potassium Channels in Epilepsy
    Downloaded from http://perspectivesinmedicine.cshlp.org/ on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Potassium Channels in Epilepsy Ru¨diger Ko¨hling and Jakob Wolfart Oscar Langendorff Institute of Physiology, University of Rostock, Rostock 18057, Germany Correspondence: [email protected] This review attempts to give a concise and up-to-date overview on the role of potassium channels in epilepsies. Their role can be defined from a genetic perspective, focusing on variants and de novo mutations identified in genetic studies or animal models with targeted, specific mutations in genes coding for a member of the large potassium channel family. In these genetic studies, a demonstrated functional link to hyperexcitability often remains elusive. However, their role can also be defined from a functional perspective, based on dy- namic, aggravating, or adaptive transcriptional and posttranslational alterations. In these cases, it often remains elusive whether the alteration is causal or merely incidental. With 80 potassium channel types, of which 10% are known to be associated with epilepsies (in humans) or a seizure phenotype (in animals), if genetically mutated, a comprehensive review is a challenging endeavor. This goal may seem all the more ambitious once the data on posttranslational alterations, found both in human tissue from epilepsy patients and in chronic or acute animal models, are included. We therefore summarize the literature, and expand only on key findings, particularly regarding functional alterations found in patient brain tissue and chronic animal models. INTRODUCTION TO POTASSIUM evolutionary appearance of voltage-gated so- CHANNELS dium (Nav)andcalcium (Cav)channels, Kchan- nels are further diversified in relation to their otassium (K) channels are related to epilepsy newer function, namely, keeping neuronal exci- Psyndromes on many different levels, ranging tation within limits (Anderson and Greenberg from direct control of neuronal excitability and 2001; Hille 2001).
    [Show full text]
  • Towards Mutation-Specific Precision Medicine in Atypical Clinical
    International Journal of Molecular Sciences Review Towards Mutation-Specific Precision Medicine in Atypical Clinical Phenotypes of Inherited Arrhythmia Syndromes Tadashi Nakajima * , Shuntaro Tamura, Masahiko Kurabayashi and Yoshiaki Kaneko Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi 371-8511, Gunma, Japan; [email protected] (S.T.); [email protected] (M.K.); [email protected] (Y.K.) * Correspondence: [email protected]; Tel.: +81-27-220-8145; Fax: +81-27-220-8158 Abstract: Most causal genes for inherited arrhythmia syndromes (IASs) encode cardiac ion channel- related proteins. Genotype-phenotype studies and functional analyses of mutant genes, using heterol- ogous expression systems and animal models, have revealed the pathophysiology of IASs and enabled, in part, the establishment of causal gene-specific precision medicine. Additionally, the utilization of induced pluripotent stem cell (iPSC) technology have provided further insights into the patho- physiology of IASs and novel promising therapeutic strategies, especially in long QT syndrome. It is now known that there are atypical clinical phenotypes of IASs associated with specific mutations that have unique electrophysiological properties, which raises a possibility of mutation-specific precision medicine. In particular, patients with Brugada syndrome harboring an SCN5A R1632C mutation exhibit exercise-induced cardiac events, which may be caused by a marked activity-dependent loss of R1632C-Nav1.5 availability due to a marked delay of recovery from inactivation. This suggests that the use of isoproterenol should be avoided. Conversely, the efficacy of β-blocker needs to be examined. Patients harboring a KCND3 V392I mutation exhibit both cardiac (early repolarization syndrome and Citation: Nakajima, T.; Tamura, S.; paroxysmal atrial fibrillation) and cerebral (epilepsy) phenotypes, which may be associated with a Kurabayashi, M.; Kaneko, Y.
    [Show full text]
  • Fifty Years of Genetic Epidemiology, with Special Reference to Japan
    J Hum Genet (2006) 51:269–277 DOI 10.1007/s10038-006-0366-9 MINIREVIEW Newton E. Morton Fifty years of genetic epidemiology, with special reference to Japan Received: 13 December 2005 / Accepted: 18 December 2005 / Published online: 15 February 2006 Ó The Japan Society of Human Genetics and Springer-Verlag 2006 Abstract Genetic epidemiology deals with etiology, dis- Introduction tribution, and control of disease in groups of relatives and with inherited causes of disease in populations. It The Japan Society of Human Genetics (JSHG) was took its first steps before its recognition as a discipline, established at a time when the science it represented was and did not reach its present scope until the Human growing so explosively that Carlson (2004) signalised the Genome Project succeeded. The intimate relationship death of classical genetics. Compared to their predeces- between genetics and epidemiology was discussed by sors, geneticists in 1956 were more distrustful of eugenics Neel and Schull (1954), just a year after Watson and and more committed to cytogenetics, biochemistry, and Crick reported the DNA double helix, and 2 years be- medical genetics, but not yet prepared for the genomic fore human cytogenetics and the Japan Society of Hu- revolution that the double helix would ultimately bring man Genetics were founded. It is convenient to divide (Yanase 1997). Population genetics was beginning to the next half-century into three phases. The first of these split into two major branches, one concerned with events (1956–1979) was before DNA polymorphisms were that took place in the past under poorly known forces of typed, and so the focus was on segregation and linkage systematic pressure and chance (evolutionary genetics), of major genes, cytogenetics, population studies, and the other dealing with etiology, distribution, and control biochemical genetics.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Manual for Conducting a Large-Scale GWAS and Whole Genome
    (COVNET) NIH Lead Investigator: Stephen Chanock, M.D. ([email protected]) Director, Division of Cancer Epidemiology and Genetics, NCI NIH Investigators: Sharon Savage, M.D. ([email protected]) Lisa Mirabello, Ph.D. ([email protected]) Meredith Yeager, Ph.D. ([email protected]) Mitchell Machiela, Sc.D. ([email protected]) Joshua Sampson, Ph.D. ([email protected]) Amy Hutchinson, M.S. ([email protected]) Belynda Hicks, M.S. ([email protected]) Division of Cancer Epidemiology and Genetics, NCI Mary Carrington, Ph.D. ([email protected]) Center for Cancer Research, NCI Leslie Biesecker, M.D. ([email protected]) Teri Manolio, M.D., Ph.D. ([email protected]) National Human Genome Research Institute Steven Holland, M.D. ([email protected]) National Institute of Allergy and Infectious Diseases Project Manager Vibha Vij, M.S., MPH ([email protected]) Division of Cancer Epidemiology and Genetics, NCI Website: https://dceg.cancer.gov/research/how-we-study/genomic-studies/covnet Table of Contents Sections 1.0 Background and Rationale for a Large Crowdsourced GWAS of COVID19 Infection ...... 2 2.0 Biospecimens: genomic DNA, blood/blood products, buccal cells/saliva .......................... 6 3.0 Patient Phenotypes ............................................................................................................. 10 4.0 Genotyping and Imputation ............................................................................................... 10 5.0 Analysis Plan ....................................................................................................................
    [Show full text]
  • Variants in the KCNE1 Or KCNE3 Gene and Risk of Ménière’S Disease: a Meta-Analysis
    Journal of Vestibular Research 25 (2015) 211–218 211 DOI 10.3233/VES-160569 IOS Press Variants in the KCNE1 or KCNE3 gene and risk of Ménière’s disease: A meta-analysis Yuan-Jun Li, Zhan-Guo Jin and Xian-Rong Xu∗ The Center of Clinical Aviation Medicine, General Hospital of Air Force, Beijing, China Received 1 August 2015 Accepted 8 December 2015 Abstract. BACKGROUND: Ménière’s disease (MD) is defined as an idiopathic disorder of the inner ear characterized by the triad of tinnitus, vertigo, and sensorineural hearing loss. Although many studies have evaluated the association between variants in the KCNE1 or KCNE3 gene and MD risk, debates still exist. OBJECTIVE: Our aim is to evaluate the association between KCNE gene variants, including KCNE1 rs1805127 and KCNE3 rs2270676, and the risk of MD by a systematic review. METHODS: We searched the literature in PubMed, SCOPUS and EMBASE through May 2015. We calculated pooled odds ra- tios (OR) and 95% confidence intervals (CIs) using a fixed-effects model or a random-effects model for the risk to MD associated with different KCNE gene variants. The heterogeneity assumption decided the effect model. RESULTS: A total of three relevant studies, with 302 MD cases and 515 controls, were included in this meta-analysis. The results indicated that neither the KCNE1 rs1805127 variant (for G vs. A: OR = 0.724, 95%CI 0.320, 1.638, P = 0.438), nor the KCNE3 rs2270676 variant (for T vs. C: OR = 0.714, 95%CI 0.327, 1.559, P = 0.398) was associated with MD risk.
    [Show full text]
  • Oegtp - Epilepsy Test Requisition Lab Use Only: Patient Information
    OEGTP - EPILEPSY TEST REQUISITION LAB USE ONLY: PATIENT INFORMATION: Received date: Name: Notes: Address: Date of Birth: YY/MM/DD Sex: M F Health Card No: TEST REQUEST: See page 2 for gene list for each of the panels below Epilepsy Comprehensive panel: 167 genes Childhood Onset Epilepsy panel: 45 genes Focal Epilepsy panel: 14 genes Brain Malformation Epilepsy panel: 44 genes London Health Sciences Centre – (Molecular Genetics) London Health Sciences Centre Progressive Myoclonic Epilepsy panel: 20 genes Actionable Gene Epilepsy panel: 22 genes Early Infantile Epilepsy panel: 51 genes Single gene test: Carrier Testing/ KnownFamily Mutation SAMPLE COLLECTION: Name of index case in the family (include copy of report) Date drawn: YY/MM/DD EDTA blood (lavender top) (5ml at room temp) Affected Unaffected Date of Birth: Relationship to patient: REFERRING PHYSICIAN: Authorized Signature is Required Gene: RefSeq:NM Physician Name (print): Mutation: Signature: Email: REASON FOR REFERRAL: Clinic/Hospital: Diagnostic Testing Address: Clinical Diagnosis: Telephone: Fax: CC report to: Name: Clinical Presentation: Address: Telephone: Fax: Molecular Genetics Laboratory Victoria Hospital, Room B10-123A 800 Commissioners Rd. E. London, Ontario | N6A 5W9 Pathology and Laboratory Medicine Ph: 519-685-8122 | Fax: 519-685-8279 Page 1 of 6 Page OEGTP (2021/05/28) OEGTP - EPILEPSY TEST PANELS Patient Identifier: COMPREHENSIVE EPILEPSY PANEL: 167 Genes ACTB, ACTG1, ADSL, AKT3, ALDH7A1, AMT, AP3B2, ARFGEF2, ARHGEF9, ARV1, ARX, ASAH1, ASNS, ATP1A3, ATP6V0A2, ATP7A,
    [Show full text]